Low Dose Epcoritamab Plus GemOx in R/R DLBCL

In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.

Trial Details

NCT ID
NCT07451652
Phase
PHASE2
Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Epcoritamab
  • Gemcitabine (1000 mg/m2)
  • Oxaliplatin
Locations (sample)
  • Monterrey, Nuevo León, Mexico|25.68435,-100.31721

Key Eligibility Criteria

  • Subjects with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to …
  • Women of reproductive age who agree on getting a contraceptive method
  • Subjects who fulfill Lugano´s criteria for disease activity
  • Subjects who voluntarily accept to participate in this study

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →